| |
Commercial
|
Medicare
|
|---|
| |
FN in Cycle
| |
FN in Cycle
|
|---|
|
No. (%) in Each Category
|
No
|
Yes
|
Unadjusted OR (95% CI)
|
No. (%) in Each Category
|
No
|
Yes
|
Unadjusted OR (95% CI)
|
|---|
|
Cycle 1
|
50,778
|
48,157 (95%)
|
2621 (5%)
| |
71,037
|
64,249 (90%)
|
6788 (10%)
| |
|
Use of Pegfilgrastim Prophylaxis
|
|
No
|
16,512 (33%)
|
15,234 (92%)
|
1278 (8%)
|
–
|
20,195 (28%)
|
17,901 (89%)
|
2294 (11%)
|
–
|
|
Yes
|
34,266 (67%)
|
32,923 (96%)
|
1343 (4%)
|
2.1 (1.9–2.2)
|
50,842 (72%)
|
46,348 (91%)
|
4494 (9%)
|
1.3 (1.3–1.4)
|
|
Cycle 2
|
41,769
|
40,810 (98%)
|
959 (2%)
| |
59,412
|
56,343 (95%)
|
3069 (5%)
| |
|
Use of Pegfilgrastim Prophylaxis
|
|
No
|
11,719 (28%)
|
11,353 (97%)
|
366 (3%)
|
–
|
15,193 (26%)
|
14,282 (94%)
|
911 (6%)
|
–
|
|
Yes
|
30,050 (72%)
|
29,457 (98%)
|
593 (2%)
|
1.6 (1.4–1.8)
|
44,219 (74%)
|
42,061 (95%)
|
2158 (5%)
|
1.2 (1.1–1.3)
|
|
Cycles ≥3
|
98,075
|
96,006 (98%)
|
2069 (2%)
| |
141,495
|
134,363 (95%)
|
7132 (5%)
| |
|
Use of Pegfilgrastim Prophylaxis
|
|
No
|
24,834 (25%)
|
24,229 (98%)
|
605 (2%)
|
–
|
43,012 (30%)
|
40,842 (95%)
|
2170 (5%)
|
–
|
|
Yes
|
73,241 (75%)
|
71,777 (98%)
|
1464 (2%)
|
1.2 (1.1–1.3)
|
98,483 (70%)
|
93,521 (95%)
|
4962 (5%)
|
1.0 (1.0–1.1)
|
|
Last Cycle
|
34,860
|
33,426 (96%)
|
1434 (4%)
| |
51,989
|
45,392 (87%)
|
6597 (13%)
| |
|
Use of Pegfilgrastim Prophylaxis
|
|
No
|
10,188 (29%)
|
9705 (95%)
|
483 (5%)
|
–
|
20,099 (39%)
|
17,851 (89%)
|
2248 (11%)
|
–
|
|
Yes
|
24,672 (71%)
|
23,721 (96%)
|
951 (4%)
|
1.2 (1.1–1.4)
|
31,890 (61%)
|
27,541 (86%)
|
4349 (14%)
|
0.8 (0.8–0.8)
|
|
All Cycles
|
190,622
|
184,973 (97%)
|
5649 (3%)
| |
271,944
|
254,955 (94%)
|
16,989 (6%)
| |
|
Use of Pegfilgrastim Prophylaxis
|
|
No
|
53,065 (28%)
|
50,816 (96%)
|
2249 (4%)
|
–
|
78,400 (29%)
|
73,025 (93%)
|
5375 (7%)
|
–
|
|
Yes
|
137,557 (72%)
|
134,157 (98%)
|
3400 (2%)
|
1.7 (1.7–1.8)
|
193,544 (71%)
|
181,930 (94%)
|
11,614 (6%)
|
1.2 (1.1–1.2)
|
- FN febrile neutropenia
- *Only consecutive qualifying cycles, beginning with cycle 1, were considered in this analysis
